Skip to main content
TipRanks
Go Ultimate75% OFF

Resverlogix (RVX) AI Stock Analysis

34 Followers
TSE:RVX

Resverlogix

(TSX:RVX)

Select Model
Rating:40Underperform
Price Target:CAD 0.07â–¼(-5.33% Downside)
Action:reiterated
Date:11/16/26

Primarily impacted by poor financial performance with zero revenue and negative equity. Weak technical signals add downward pressure, while valuation metrics align with the high-risk profile of an early-stage biotech.

Positive Factors
Focused Epigenetic Drug PlatformA defined focus on small-molecule epigenetic therapies gives Resverlogix a coherent development strategy and concentrates resources around related cardiovascular and metabolic applications. This specialization could support cumulative scientific and intellectual-property value as programs advance.
Negative Factors
No Revenue and Worsening Lossesไม่มี revenue leaves Resverlogix without operating income to fund research, while the larger TTM loss shows profitability has deteriorated. Continued negative EBIT and EBITDA limit operating leverage and make progress dependent on successful development or external financing.

Resverlogix (RVX) vs. iShares MSCI Canada ETF (EWC)

-40%-30%-20%-10%0%10%20%30%40%TSE:RVX-28.57%EWC+17.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 25.82M
Dividend Yield
―
Average Volume (3M)
34.16K
Price to Earnings (P/E)
-1.6
Beta (1Y)
0.71
Revenue Growth
―
EPS Growth
-28.45%
Country
Canada
Employees
17
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Resverlogix Business Overview & Revenue Model

Company Description

Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalon...

Resverlogix Financial Statement Overview

Summary

Resverlogix reports zero revenue with persistent net losses, deeply negative equity over $94M, high debt near $77M, and ongoing negative cash flows, posing significant sustainability risks.

Income Statement

15Very Negative

Balance Sheet

8Very Negative

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Dec 2022Mar 2022
Income Statement
Total Revenue000000
Gross Profit-359.05K-437.53K-476.75K―00
EBITDA-5.46M-4.77M-4.25M-4.46M-11.74M-14.87M
Net Income-10.33M-7.90M-7.63M-16.74M-3.61M-24.77M
Balance Sheet
Total Assets8.47M7.93M7.34M6.57M8.12M9.98M
Cash, Cash Equivalents and Short-Term Investments156.99K107.80K99.00K5,00040.00K6,000
Total Debt77.18M72.77M81.97M9.91M6.49M7.04M
Total Liabilities102.83M96.73M89.08M81.04M67.40M69.85M
Stockholders Equity-94.36M-88.80M-81.73M-74.47M-59.28M-59.87M
Cash Flow
Free Cash Flow-4.89M-3.73M-4.36M-2.96M-3.99M-8.90M
Operating Cash Flow-4.68M-3.73M-3.89M-2.51M-3.54M-8.02M
Investing Cash Flow-679.15K-660.36K-377.00K-516.00K-473.00K-833.00K
Financing Cash Flow5.44M4.39M4.36M2.99M4.06M8.81M

Resverlogix Technical Analysis

Technical Analysis SentimentNegative
Last Price0.07

Price Trends

50DMA0.08Negative
100DMA0.09Negative
200DMA0.10Negative

Market Momentum

MACD-0.00Negative
RSI46.52Neutral
STOCH100.00Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RVX, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.10, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 46.52 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RVX.

Resverlogix Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:RVX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:MBXTSE:MBX52NeutralCAD 40.41M-8.07-18.83%―-27.13%-1752.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:BCTTSE:BCT42NeutralCAD 43.23M-0.37-170.70%――87.90%
TSE:RVXTSE:RVX40UnderperformCAD 25.82M-1.6211.24%――-28.45%

* Healthcare Sector Average

Performance Comparison

-50%0%50%TSE:RVXTSE:BCTTSE:MBXTSE:GSDTSE:TTIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:RVX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:RVXResverlogix Corp.0.07-0.03-28.57%
TSE:BCTBriaCell Therapeutics4.95-5.15-50.99%
TSE:MBXMicrobix Biosystms0.290.0522.92%
TSE:GSDDevonian Health Group, Inc.6.30-5.40-46.15%
TSE:TTIThiogenesis Therapeutics Corp0.60-0.05-7.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 16, 2026